Journal of Ophthalmology / 2018 / Article / Tab 6

Research Article

Verisyse versus Veriflex Phakic Intraocular Lenses: Refractive Outcomes and Endothelial Cell Density 5 Years after Surgery

Table 6

Endothelial changes over the course of the study.

Preoperative1 year3 years5 years

Central ECD (cells/mm2) (mean ± SD (% of cumulative ECD loss))
Verisyse2681 ± 275 (N/A)2599 ± 242 (3.05)2534 ± 238 (5.48)2482 ± 242 (7.42)
Veriflex2656 ± 270 (N/A)2575 ± 253 (3.04)2512 ± 251 (5.42)2460 ± 282 (7.64)
0.6920.6700.6780.709

Coefficient of variation of cell area (%)
Verisyse30.8 ± 5.529.0 ± 5.729.4 ± 4.329.1 ± 5.80.083
Veriflex30.0 ± 5.230.6 ± 5.230.5 ± 5.431.2 ± 6.00.233
0.5150.1850.6990.117

Hexagonal cells (%)
Verisyse65.4 ± 7.566.1 ± 7.364.8 ± 6.966.0 ± 8.20.114
Veriflex62.7 ± 7.764.7 ± 8.463.9 ± 8.264.4 ± 8.80.142
0.1300.4220.6010.396

Repeated measures ANOVA, value for all visits. Independent samples t-test. Post hoc analysis: statistically significant difference was observed from the preoperative visit to the 1-year visit (), from the 1-year visit to 3-year visit (), and from 3-year visit to 5-year visit (). ††Post hoc analysis: statistically significant difference was observed from the preoperative visit to the 1-year visit (), from the 1-year visit to 3-year visit (), and from 3-year visit to 5-year visit ().

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.